Role of the Built Environment in the Recovery From COVID-19: Evidence From a GIS-Based Natural Experiment on the City Blocks in Wuhan, China

The built environment closely relates to the development of COVID-19 and post-disaster recovery. Nevertheless, few studies examine its impacts on the recovery stage and corresponding urban development strategies. This study examines the built environment's role in Wuhan's recovery at the city block level through a natural experiment. We first aggregated eight built environmental characteristics (BECs) of 192 city blocks from the perspectives of density, infrastructure supply, and socioeconomic environment;then, the BECs were associated with the recovery rates at the same city blocks, based on the public "COVID-19-free" reports of about 7,100 communities over the recovery stages. The results showed that three BECs, i.e., "number of nearby designated hospitals," "green ratio," and "housing price" had significant associations with Wuhan's recovery when the strict control measures were implemented. At the first time of reporting, more significant associations were also found with "average building age," "neighborhood facility development level," and "facility management level." In contrast, no associations were found for "controlled residential land-use intensity" and "plot ratio" throughout the stages. The findings from Wuhan's recovery pinpointing evidence with implications in future smart and resilient urban development are as follows: the accessibility of hospitals should be comprehensive in general;and the average housing price of a city block can reflect its post-disaster recoverability compared to that of the other blocks.

[Potential antiviral therapeutics for 2019 Novel Coronavirus].

The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-ß, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.